• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by Gregory John Beattie

    2/16/21 4:01:49 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $BASI alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Beattie John Gregory

    (Last) (First) (Middle)
    C/O BIOANALYTICAL SYSTEMS, INC.
    2701 KENT AVENUE

    (Street)
    WEST LAFAYETTE IN 47906

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/15/2021
    3. Issuer Name and Ticker or Trading Symbol
    BIOANALYTICAL SYSTEMS INC [ BASI ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Operating Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit List: Exhibit 24.1 -- Power of Attorney
    No securities are beneficially owned.
    /s/ Beth A. Taylor, attorney-in-fact for John Gregory Beattie 02/15/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BASI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BASI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Beth Taylor bought $88,500 worth of Common Shares (5,000 units at $17.70), increasing direct ownership by 17% to 34,295 units

    4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)

    3/5/21 4:41:23 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4: Gregory John Beattie bought $31,843 worth of Common Shares (1,712 units at $18.60), increasing ownership by 7% to 25,000 units

    4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)

    3/1/21 4:14:24 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4: Gregory John Beattie bought $116,032 worth of Common Shares (8,288 units at $14.00), increasing ownership by 55% to 23,288 units

    4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)

    2/25/21 4:03:55 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc.

    WEST LAFAYETTE, Ind., March 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of nonclinical and analytical contract research services, today announced a change of the Company’s corporate name from Bioanalytical Systems, Inc. to Inotiv, Inc. The name change was approved by the Company’s shareholders on March 18, 2021, at the Company’s annual meeting of shareholders and became effective as of the filing of articles of amendment to the Company’s Second Amended and Restated Articles of Incorporation, as amended, that same day. Effective Monday, March 22, 2021, The Company’s common shares will trade under the ti

    3/19/21 4:05:00 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology

    WEST LAFAYETTE, Ind., March 17, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced plans to expand the Company’s service offerings to add cardiovascular safety pharmacology capabilities to the existing capabilities for respiratory and central nervous system safety pharmacology. Safety pharmacology evaluations are critical for assessing the impact of drug candidates. By summer 2021, Inotiv expects to offer integrated safety pharmacology packages that include core battery tests for cardiovascular, respiratory, and ce

    3/17/21 8:33:00 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN

    WEST LAFAYETTE, Ind., March 09, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services continues to invest in expanding services and adding capacity to meet client needs and growth expectations. In line with these goals, the Company has been expanding and further developing its West Lafayette vivarium. Last month, the additional West Lafayette capacity was successfully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. The Company believes this is an important step fo

    3/9/21 8:33:00 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    SEC Filings

    View All

    SEC Form RW filed by Bioanalytical Systems, Inc.

    RW - Basis Global Technologies, Inc. (0001330016) (Filer)

    11/3/22 2:09:08 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 8-K filed by Bioanalytical Systems, Inc.

    8-K - Inotiv, Inc. (0000720154) (Filer)

    3/19/21 4:30:11 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 8-K filed

    8-K - BIOANALYTICAL SYSTEMS INC (0000720154) (Filer)

    3/9/21 6:06:06 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Colliers Securities resumed coverage on Bioanalytical Systems with a new price target

    Colliers Securities resumed coverage of Bioanalytical Systems with a rating of Buy and set a new price target of $17.00

    3/9/21 4:15:07 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Leadership Updates

    Live Leadership Updates

    View All

    Bioanalytical Systems, Inc., doing business as Inotiv, Appoints Greg Beattie as Chief Operating Officer

    WEST LAFAYETTE, Ind., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the appointment of Greg Beattie as Chief Operating Officer of the Company, effective February 15, 2021. Mr. Beattie brings more than 30 years of contract research experience to the Company, including more than two decades in operational leadership roles at Charles River Laboratories, where he drove growth and profitability across multiple business units. During his career at Charles River Laboratories, Mr. Beattie held Corporate Vice

    2/11/21 4:05:00 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed

    SC 13G - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)

    2/16/21 3:42:04 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed

    SC 13G - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)

    2/10/21 9:57:05 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)

    2/3/21 1:35:55 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care